Phreesia, Inc. (NYSE:PHR) Receives Consensus Rating of “Moderate Buy” from Brokerages

Shares of Phreesia, Inc. (NYSE:PHR) have received an average recommendation of “Moderate Buy” from the twelve brokerages that are currently covering the stock, Marketbeat reports. One equities research analyst has rated the stock with a hold rating and eleven have assigned a buy rating to the company. The average 12-month price target among brokerages that have issued a report on the stock in the last year is $29.42.

Several brokerages have commented on PHR. JPMorgan Chase & Co. upped their price objective on Phreesia from $27.00 to $28.00 and gave the company an “overweight” rating in a research report on Monday, September 9th. DA Davidson reaffirmed a “buy” rating and issued a $32.00 price target on shares of Phreesia in a research note on Thursday, September 5th. Robert W. Baird boosted their price objective on shares of Phreesia from $31.00 to $34.00 and gave the company an “outperform” rating in a research report on Friday, September 6th. Royal Bank of Canada reaffirmed a “sector perform” rating and set a $23.00 target price on shares of Phreesia in a research report on Friday, September 27th. Finally, Truist Financial lifted their price target on shares of Phreesia from $29.00 to $31.00 and gave the company a “buy” rating in a research note on Friday, September 6th.

Phreesia Stock Performance

NYSE PHR opened at $20.33 on Wednesday. The business’s 50 day moving average price is $20.63 and its 200-day moving average price is $21.89. The company has a market cap of $1.17 billion, a P/E ratio of -11.29 and a beta of 0.94. The company has a debt-to-equity ratio of 0.03, a quick ratio of 1.77 and a current ratio of 1.77. Phreesia has a fifty-two week low of $14.55 and a fifty-two week high of $29.16.

Phreesia (NYSE:PHR) last announced its quarterly earnings data on Wednesday, September 4th. The company reported ($0.31) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.37) by $0.06. The business had revenue of $102.12 million during the quarter, compared to the consensus estimate of $101.76 million. Phreesia had a negative net margin of 25.73% and a negative return on equity of 39.34%. Sell-side analysts predict that Phreesia will post -1.23 earnings per share for the current year.

Insiders Place Their Bets

In related news, SVP David Linetsky sold 1,716 shares of the stock in a transaction that occurred on Tuesday, September 10th. The shares were sold at an average price of $23.25, for a total transaction of $39,897.00. Following the completion of the sale, the senior vice president now owns 203,318 shares of the company’s stock, valued at $4,727,143.50. This represents a 0.84 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, insider Yvonne Hui sold 2,791 shares of the firm’s stock in a transaction that occurred on Tuesday, October 15th. The shares were sold at an average price of $20.92, for a total transaction of $58,387.72. Following the completion of the sale, the insider now owns 27,228 shares of the company’s stock, valued at approximately $569,609.76. This trade represents a 9.30 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 29,997 shares of company stock worth $667,943 over the last 90 days. Company insiders own 5.80% of the company’s stock.

Institutional Trading of Phreesia

Hedge funds and other institutional investors have recently made changes to their positions in the business. Champlain Investment Partners LLC increased its holdings in shares of Phreesia by 4.1% during the third quarter. Champlain Investment Partners LLC now owns 2,503,837 shares of the company’s stock valued at $57,062,000 after acquiring an additional 97,847 shares in the last quarter. State Street Corp boosted its stake in Phreesia by 7.1% in the 3rd quarter. State Street Corp now owns 1,327,586 shares of the company’s stock worth $30,256,000 after purchasing an additional 88,517 shares in the last quarter. Geode Capital Management LLC grew its position in Phreesia by 4.7% during the 3rd quarter. Geode Capital Management LLC now owns 1,245,797 shares of the company’s stock worth $28,397,000 after purchasing an additional 55,934 shares during the last quarter. TimesSquare Capital Management LLC grew its position in Phreesia by 2.3% during the 3rd quarter. TimesSquare Capital Management LLC now owns 868,409 shares of the company’s stock worth $19,791,000 after purchasing an additional 19,395 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. increased its stake in Phreesia by 3.7% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 447,239 shares of the company’s stock valued at $10,193,000 after purchasing an additional 16,112 shares in the last quarter. Hedge funds and other institutional investors own 92.10% of the company’s stock.

Phreesia Company Profile

Phreesia, Inc provides an integrated SaaS-based software and payment platform for the healthcare industry in the United States and Canada. The company offers access solutions that offers appointment scheduling system for online appointments, reminders, and referral tracking management; registration solution to automate patient self-registration; revenue cycle solution, which offer insurance-verification processes, point-of-sale payments applications, post-visit payment collection, and flexible payment options; and network connect solution to deliver clinically relevant content to patients.